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Abstract 
The optimal management of local recur-
rences after primary resection of pancreatic
cancer still remains to be clarified. A 58-year-
old woman developed an isolated recurrence of
pancreatic cancer six year after distal pancrea-
tectomy. Re-resection was attempted but the
lesion was deemed unresectable at surgery.
Then chemotherapy was administrated with-
out obtaining a reduction of the tumor size nor
an improvement of the patient’s symptoms.
Thus the patient underwent percutaneous
cryoablation under computed tomography
(CT)-guidance obtaining tumor necrosis and a
significant improvement in the quality of life.
A CT scan one month later showed a stable
lesion with no contrast enhancement. While
the use of percutaneous cryoblation has
widened its applications in patients with unre-
sectable pancreatic cancer, it has never been
described for the treatment of local pancreatic
cancer recurrence after primary resection.
Percutaneous cryoablation deserves further
studies in the multimodality treatment of local
recurrence after primary pancreatic surgery.
Introduction
Pancreatic cancer represents the fourth
leading cause of cancer-related death in the
Western world and still has a poor prognosis,
in spite of the progresses achieved in cancer
treatment over the last decades.1-3 Surgical
resection is considered the only curative treat-
ment for localized pancreatic adenocarcinoma,
although it is known that only 15 to 20% of
patients are candidates for resection surgery.4
Local and distant recurrences are common,
even after radical surgery and adjuvant treat-
ment. Local recurrences are linked with poor
prognosis and possible onset of severe symp-
toms, such as excruciating pain, jaundice and
hemorrhage.5 The management of these
lesions is challenging due to both the objective
difficulties of redoing surgical resection with a
curative intent and the common coexistence of
distant metastases.2,6,7
Case Report
A 58-year-old year lady underwent open dis-
tal pancreatectomy for a moderately differenti-
ated pancreatic adenocarcinoma measuring
20x10 mm with no peripancreatic lymph node
metastases, followed by adjuvant chemothera-
py. She had been well without recurrence of
cancer for six years following primary treat-
ment, when she started to complain of moder-
ate to severe abdominal pain, dyspepsia and
weight loss. An ultrasound scan revealed a
hypoechoic lesion measuring 16x18 mm in the
pancreatic head. The patient was then sent for
a contrast-enhanced computed tomography
(CT) scan that showed an irregular mass locat-
ed in the head of the pancreas (Figure 1). A
CT-guided fine-needle aspiration cytology con-
firmed the lesion to be a cancer recurrence. A
fluorodeoxyglucose positron emission tomog-
raphy/CT study showed intense radiotracer
accumulation in the pancreatic head. Since no
signs of distant metastases were present at
metastatic work-up, the patient underwent an
exploratory celiotomy for salvage surgery.
However, the cancer recurrence was deemed
unresectable at the time of surgery because of
tight adhesions and the lack of any cleavage
planes with the hepatic artery and the portal
vein. Therefore, first-line chemotherapy with
cisplatin-gemcitabine combination was
administered. Since the lesion in the pancreat-
ic head had increased to 25x30 mm at the fol-
low-up CT scan, a second-line chemotherapy
with oxaliplatine was given. Nonetheless, a CT
scan revealed a progression of disease (tumor
mass maximum diameter 30x30 mm).
Fourteen months after the diagnosis of cancer
recurrence the patient underwent CT-guided
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Figure 1. Computed tomography scan after six years from primary distal pancreatectomy
for ductal adenocarcinoma showing an enlargement of the pancreatic head containing a
mass (arrow) measuring 28x23 mm, isodense at baseline examination (A), relatively
hypodense after rapid contrast medium injection (arterial phase) (B), and isodense in the
portal phase (C).
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percutaneous cryoablation (PCA) under local
anesthesia and conscious sedation, using a
tabletop argon gas-based cryoablation system
(Galil Medical, Yokeneam, Israel). Two cry-
oprobes (Icesed®) were inserted under CT-
guidance (Figure 2) into the tumor for double
intraprocedurally freezing thawing cycles.
Under CT guidance, the needle’s position and
the ice ball dimensions (Figure 3) were
assessed. There were no procedure-related
complications and the postoperative period
was uneventful. We only observed a low (and
asymptomatic) increase of serum amylase and
lipase the day after the procedure, which
returned to normal in five days. The patient
was discharged on postoperative day 2. One
month after the treatment the patient was
asymptomatic and contrast-enhanced CT scan
showed no enhancement of the treated lesion
(Figure 4). Three months after the PCA proce-
dure the patient was lost to follow-up.
Discussion
Local recurrence following pancreatic resec-
tion for cancer occurs in 35-86% of patients
operated on with curative intent.8,9 While local
relapses are often detected in conjunction with
disseminated disease, there is a smaller group
of patients (approximately 30%), where isolated
local recurrence is observed without evidence of
distant metastasis.6,10
To date, no standard treatment or supportive
care guidelines exist for the management of
this severe condition.6,10 Systemic chemothera-
py has historically resulted in a median sur-
vival rate of 5-11 months,4,11 and also radiation
therapy has been shown to result in significant
local control and to have some survival effects
in selected patients.10 
Some authors suggest that redo surgery
could be effective and prolong survival in
selected patients; however morbidity rates for
repeated pancreatic resection can be associat-
ed to high morbidity rates due to adhesions,
anatomical complexities and post-radiation
fibrosis.9 Moreover, patients with local recur-
rences are frequently not good surgical candi-
dates because of the poor general conditions.6
In the case described herein, a re-resection
was attempted, but unfortunately it was not
possible to remove the recurrence located in
the pancreatic head because of the adhesions
and possible infiltration of the hepatic artery
and portal vein. 
During the last ten years different minimally
invasive ablative methods have been emerging
for the palliative treatment of pancreatic
cancer.2,12 Cryoablation is an ablative method
which has been widely used for the treatment of
several benign and malignant solid tumors.4,5,12-14
In essence, its effectiveness is based on the spe-
cific cytotoxic effects of cold on tissue that pro-
duces both instant and delayed destruction of
cellular ultrastructure at temperatures lower
than –40°C.2,4,13 Cryoablation has been predom-
inantly performed during either open or laparo-
scopic surgery.12 Ultrasound or CT-guided PCA
is a relatively new method used for the treat-
ment of various solid malignancies.12
Acceptance of PCA for pancreatic malignancies
has been delayed by concerns regarding both
technical difficulties and risk of complications,
in that the pancreas has a soft texture, has a
profound location in the abdomen, and is close
to structures such as the duodenum, portal vein,
superior mesenteric artery, hepatic artery and
common bile duct. However, recent advances in
image-guided percutaneous techniques and
instruments have led to a surge in the applica-
tion of PCA in patients with pancreatic cancer.2,3
                                                                                                                     Case Report
Figure 2. Patient in the computed tomog-
raphy-room during the percutaneous
cryoablation procedure.
Figure 3. Two cryoprobes (Icesed®) with active tip positioned within the tumor were
inserted under computed tomography (CT)-guidance with the patient in the supine posi-
tion (A, B). The CT scan performed during the freezing phase showed an hypodense area
located in the site of the tumor, corresponding to the ice ball (C).
Figure 4. Modifications of the tumor seen at computed tomography (CT) scan at the time
of initial diagnosis (A), during the percutaneous cryoablation (PCA) procedure (B), and
after one month (C). Repeat CT scan after one month showed a well-defined and homo-
geneously hypodense area of 3x3 cm in the pancreatic head, corresponding to the coag-
ulation necrosis obtained by PCA.
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In fact, some studies and literature reviews
have shown the safety and feasibility of PCA for
unresectable or not amenable to surgery pan-
creatic cancer, although its use remains
restricted to very selected cases in expert
hands. The risk of vascular injuries from cold
temperatures is hampered by the fact that the
rapid blood flow in the large vessels close to the
pancreas has a hot pool effect.3,4
Optimal tumor freezing and prevention of
injuries to adjacent organs can be obtained
with intraprocedural monitoring using ultra-
sonography, CT, or magnetic resonance imag-
ing.2,4 Ultrasound can be used to guide PCA,
but posterior acoustic shadowing limits visual-
ization. At CT-scan the frozen lesion appears
as an ice ball that is hypodense with respect to
unfrozen tissue. For these reasons, we used
CT guidance to assess the size and the location
of the ice ball during the procedure. 
Possible minor and major adverse effects
have been described after cryoablation of pan-
creatic tumor, the main ones being abdominal
pain, fever, increased serum amylase, bleed-
ing, and leakage of pancreatic juice.2-4
However, rates of severe complications due to
cryoablation appear to be lower than observed
in other ablative techniques.12
In our patient, the postoperative period was
uneventful and the patient was discharged 2
days after the treatment. The majority of
authors report the patients undergoing PCA for
pancreatic cancer under general anesthesia.4,5
It should be noted that we performed PCA on
this patient under local anesthesia and con-
scious sedation without any intraoperative
complications. Unfortunately, the patient was
lost to follow-up after 3 months, thus it was not
possible to evaluate further the clinical course
and response to treatment. We were just able
to notice that she was asymptomatic at the
time of the one-month CT scan, hence we can
assume that the procedure had a role in ame-
liorating her initial symptoms (moderate to
severe pain and dyspepsia). Nonetheless, we
believe that this case is worthy of attention,
since PCA, as well as other ablative proce-
dures, has been gaining popularity as a mini-
mally invasive palliative procedure in patients
with unresectable locally advanced pancreatic
cancer, and several authors reported its effec-
tiveness and safety in selected patients.2,3,5,12
To the best of our knowledge, however, ours is
the first description of the use of PCA in the
setting of an isolated local recurrence of pan-
creatic cancer. Besides, the patient underwent
PCA with no complications and was discharged
on postoperative day 2.
Conclusions
The case described herein, together with
the evidence of the feasibility of cryoablation
in locally advanced pancreatic tumors, sug-
gests that PCA under CT-guidance is feasible
and safe, and deserves further attention in the
multimodality treatment of patient with local
recurrence after primary surgery for pancreat-
ic carcinoma. 
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